期刊文献+

β-肾上腺素受体激动剂与布比卡因致心肌毒性的相关性研究

下载PDF
导出
摘要 目的探讨不同浓度的非选择性β-肾上腺素受体激动剂与布比卡因致心肌毒性的相关性。方法选取成年雄性SD大鼠19只,按β-肾上腺素受体激动剂治疗浓度分为低剂量组(5.0μg/ml,6只)、中剂量组(10.0μg/ml,6只)和高剂量组(15.0μg/ml,7只)。建立动物造模:大鼠在10%水合氯醛腹腔注射麻醉后,经尾静脉以0.75mg/(kg?min)的速率持续给予布比卡因12min,40s后停止给药,期间若心电图表现为QT间期延长,则可判断布比卡因致心肌毒性,随后分别抽取肾上腺素2μg/kg、4μg/kg和6μg/kg,以生理盐水稀释至0.4ml,静脉注射,持续2~3s。于基线期(给药前)、治疗(肾上腺素给药)结束时及治疗后10min测定心室内压波形及大鼠心电图,分别记录和比较3组PR间期、QRS间期和HR等数据。结果3组基线时的左心室收缩压(left ventricular systolic pressure,LVSP)、左心室舒张末压(left ventricular enddiastolic pressure,LVEDP)、左心室内压最大上升速率(maximum ascending rate of left ventricular internal pressure,+dp/dt max)、左心室内压最大下降速率(maximum descending rate of left ventricular internal pressure,-dp/dt max)与试验前比较,差异均无统计学意义(P>0.05)。肾上腺素治疗结束时、治疗后10min时,中、高剂量组的LVSP、LVEDP、+dp/dtmax和-dp/dt max较低剂量组均显著下降,差异有统计学意义(P<0.05)。肾上腺素治疗结束时,与基线相比3组的HR均减慢;治疗后10min时肾上腺素剂量越高,HR加快也越明显,差异均有统计学意义(P<0.05)。结论肾上腺素可加重布比卡因所致心肌力学抑制效果,提高心肌毒性,但对心肌传导功能作用不明显。
出处 《北京医学》 CAS 2023年第3期260-262,共3页 Beijing Medical Journal
基金 河北省卫生健康委员会项目(20210041)。
  • 相关文献

参考文献3

二级参考文献50

  • 1Lawson WE, Hui JC, Lang G. Treatment benefit in the enhanced external counterpulsation consortium. Cardiology, 2000,94 ( 1 ) :31-35.
  • 2Ryden L, Standl E, Bartnic M, et al. Guideline on diabetes, prediabetes and cardiovascular disease:executive summary. The Task Force on Diabetes and Cardiovascular Disease of European Society of Cardiology (ESC) and of the Euopean Association for the Study of Diabetes(EASD). Eur Heart J,2007,28( 1 ) :88-136.
  • 3Crawford MH, Bernstein SJ, Deedwania PC, et al. ACC/AHA Guidelines for Ambulatory Electrocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines ( Committee to Revise the Guidelines for Ambulatory Electrocardiography). Developed in collaboration with the North American Society for Pacing and Electrophysiology.J Am Coll Cardiol,1999,34(3) :912-948.
  • 4Campeau L. Letter: Grading of angina pectoris. Circulation 1976 :54(3) :522-523.
  • 5O'Rourke RA, Brundage BH, Froelicher VF, et al. American College of Cardiology/American Heart Association Expert Consensus Document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. J Am Coll Cardiol, 2000,36(1) :326-340.
  • 6Gibbons Pal, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-sunanary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol, 2003,41 ( 1 ) : 159-168.
  • 7Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation, 2004,110(10) :1245-1250.
  • 8Girman CJ, Rhodes T, Mercuri M,et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherescleresis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol,2004,93 ( 2 ) : 136-141.
  • 9Kjekshus JK, Maroko PB, Sobel BE. Distribution of myocardial injury and its relation to epicardial ST-segment changes after coronary artery occlusion in the dog. Cardiovasc Res,1972,6(5) :490-499.
  • 10Kleber AG. ST-segment elevation in the electrocardiogram: a sign of myecaniial iechemia. Cardiovasc Res, 2000,45(1) :111-118.

共引文献2165

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部